Denali Therapeutics Inc.
DNLI
$24.20
-$0.72-2.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -511.45M | -508.02M | -512.54M | -498.74M | -479.03M |
| Total Depreciation and Amortization | 15.89M | 15.36M | 14.81M | 13.65M | 12.06M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 89.84M | 85.73M | 84.98M | 81.63M | 75.10M |
| Change in Net Operating Assets | -28.32M | -5.41M | 149.00K | 5.69M | 42.26M |
| Cash from Operations | -434.04M | -412.34M | -412.60M | -397.78M | -349.62M |
| Capital Expenditure | -3.42M | -6.89M | -9.50M | -13.07M | -18.33M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 72.40M | 337.88M | 264.78M | 419.79M | 460.88M |
| Cash from Investing | 68.98M | 330.99M | 255.28M | 406.72M | 442.55M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.42M | -3.83M | -8.17M | -16.48M | -39.13M |
| Issuance of Common Stock | 955.12M | 944.17M | 925.71M | 9.39M | 14.26M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -528.32M | -528.32M | -728.32M | 0.00 | 0.00 |
| Cash from Financing | 425.38M | 412.02M | 189.22M | -7.09M | -24.87M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 60.32M | 330.68M | 31.90M | 1.86M | 68.06M |